The European Hematology Association (EHA) is gearing up for its annual EHA 2024 Hybrid conference, which will occur from June 13 to 16, 2024, in Madrid, Spain. This is one of the most highly regarded scholarly gatherings in the international hematology science, practice, research, and hematology event calendar.
The event will foster an environment that enables the opportunity to share knowledge and ideas, encourage teamwork, and help to remain up to date on the most important discoveries in the continuously developing field of hematology.
The conference offers the option for both live and remote attendance. This makes the meeting accessible for attendees from different geographical locations and ensures that people from across the world can work together to find a solution to the challenges facing the subject in such a short span of time.
Focus on Emerging Fields
The EHA 2024 Hybrid conference will highlight two key areas within its Topics-in-Focus program:
-
Precision Hematology: It explores novel diagnostic tools and clinical trial designs to personalize patient care and accelerate the implementation of precision medicine in hematology.
-
Hemoglobinopathies: This program aims to raise awareness and education about genetic blood disorders, specifically Sickle Cell Disease, among healthcare professionals, patients, and the general public.
Unveiling the Cutting Edge of Hematology Science
The EHA2024 Hybrid conference has curated selected scientific programs that cover the sections and topics of hematological subspecialties. Attendees can expect in-depth explorations of:
-
Hemostasis and Thrombosis: The program will cover recent research on Coagulation, hypertension, and thrombosis. It is intended to develop fresh approaches to prevent blood clot formation and improve the management of hemophilia and other bleeding disorders.
Presentations will provide the latest insight into antiphospholipid syndrome, and novel oral anticoagulants for venous thromboembolism prophylaxis might lead the charge in this area.
-
Hematologic Malignancies: It will cover various blood malignancies, including leukemia, lymphoma, and myeloma, and is expected to demonstrate recent developments in targeted therapies, CAR-T cell therapy, and other emerging strategies for managing these cancers.
Attendees can look forward to hearing presentations on CAR-T cell therapy from various other presentations, including the effectiveness of FLT3 inhibitors in the treatment of AML.
-
Transfusion Medicine: The program may also cover focus areas such as blood product production, patient— and disease-specific transfusion practice, and transfusion and handling related consequences.
The discussion would include the newest data about red blood cell storage or the individual approach to platelet transfusion.
-
Stem Cell Transplantation: Participants can expect the event to cover topics like stem cell mobilization techniques, the history of stem cell conditioning, and the prevention of graft-versus-host disease (GVHD).
This section will present talks such as ‘The new ways for preventing GVHD’ by Dr. John Gribben, London, UK. Another topic will be ‘The utility of haplo-identical stem cell transplantation.’
Learning Opportunities
The EHA 2024 Hybrid conference caters to diverse learning preferences and needs by offering a variety of formats, including:
-
Plenary Lectures: Leading professionals in the field will deliver keynote plenary lectures focusing on recent findings and promising research questions on hematologic disease.
-
Oral Presentations: Attendees will be able to get acquainted with the results of current studies on countless topics related to the hematological subject and expect lively discussions.
-
Poster Sessions: This format enables the participant to discuss presenting their study in poster form with researchers.
-
Interactive Workshops: These sessions provide hands-on experience with the latest techniques and technologies in hematology, empowering participants with practical skills.
Fostering Connections and Collaboration
The EHA 2024 Hybrid conference transcends being a mere scientific forum. It is a unique platform for fostering connections and collaborations among hematology professionals. Attendees have the opportunity to:
-
Network with Industry Representatives: Gain insights into the latest diagnostic tools, therapeutic agents, and cutting-edge technologies showcased by leading hematology companies. Professionals from leading firms like AbbVie, Amgen, or Roche may attend and exhibit new scientific achievements.
-
Engage with Patient Groups: Connect with patient advocacy organizations like the Leukemia & Lymphoma Society or the European Hematology Patients’ Association to better understand patient needs and priorities. This will ultimately lead to more patient-centric treatment approaches.
-
Build International Collaborations: The event will provide network opportunities for participants worldwide to develop joint research initiatives and share best practices, accelerating advancements in hematology globally.
Presidential Sessions Speakers
The EHA 2024 Hybrid conference will have distinguished Presidential Sessions where leading hematologists present their results. Here are some of the confirmed presentations for 2024:
Saturday, June 15, 2024 – Presidential Session I
-
Conducting multinational RCTs in pregnancy to improve maternal health in thrombosis: Prof. Saskia Middeldorp (The Netherlands). This presentation is expected to discuss the retention and feasibility issues and possible advantages of using major clinical trials to assess new anticoagulant treatments for pregnant women with a history of blood clots.
-
Targeting the epigenome in lymphoma by Prof. Ari Melnick (United States). This talk will be about the spectacular biochemistry of epigenetics, where the gene-expressing pattern can be altered without any change in the DNA sequence in the context of lymphomas.
Sunday, June 16, 2024 – Presidential Session II
-
Innovative tools for disease monitoring in Multiple Myeloma by Prof. Bruno Paiva from Spain. This presentation is expected to involve the description of novel biomarkers or imaging methods to improve the measurement of multiple myeloma, a cancer stemming from the plasma cells in bone marrow.
-
Therapeutic inhibition of the complement system by Prof. Antonio Risitano from Italy. Complement systems have been implicated in playing a major role in the immune response of the body. This discussion will look at whether this system can be the target for novel drugs that can be used to treat different hematological diseases.
-
Myeloproliferative neoplasms: Are we ready to disease modify? by Prof. Claire Harrison, United Kingdom. A myeloproliferative syndrome is a type of blood cancer that causes abnormal production of blood cells. This presentation is expected to describe advancements in the therapeutic treatments of these cancers, which could focus on treating them, potentially moving beyond symptom management.
Future of Hematology
The EHA 2024 Hybrid conference has paved the way for future discussions of hematology.
-
Personalized Medicine: The conference is expected to discuss some of the novel trends in personalized medicine, which adapts the care given to individual differences in genetics and molecular composition. Such a move towards personalized and consumer-driven care plans has the potential to herald better outcomes and fewer adverse effects on the patient.
The discussion is expected to be on genomics within the framework of the individualized treatment of acute lymphoblastic leukemia (ALL) and on the personalized management of Myeloproliferative Neoplasms (MPNs).
-
Gene Editing: This invites the group to present discussions on various gene editing tools, such as CRISPR, which could be used for curative blood disorders at the genetic level. These revolutionary technologies are some of the only treatments that have the potential to bring permanent cures for various hematological malignancies.
Mr. Feng Zhang (Broad Institute, USA), a leading scientist in the CRISPR technology field, will be presenting its application in hematology.
-
Digital Hematology: The conference may showcase the use of digital technologies such as artificial intelligence and big data analysis in diagnosing, treating, and researching hematological diseases. These technologies can potentially transform essential areas such as diagnosis and treatment in hematology.
A Must-Attend Event for Hematology Professionals in 2024
The EHA 2024 Hybrid Conference is set to be a global symbol of achievement for hematology professionals. As a comprehensive scientifically diverse, engaging, and networking-rich conference with novel learning formats and a scientific program that is truly outstanding for the field of hematology, the conference remains an unrivaled opportunity to constantly update oneself and actively participate in shaping the field.
This conference brings together clinicians, researchers, industry representatives, and even patients. It offers a unique opportunity to unearth the latest developments across all haematologic subspecialties, including advanced therapies, digital aids, and personalized medicine.
